The Trump administration has pledged $812 million (AED 2.98 billion) to boost the US manufacturing of medicines needed to treat the coronavirus.
It's aimed to end dependence on other countries, and boost their own supply chain.
The four-year contract, worth $354 million, which has been awarded to Virginia-based Phlow Corp can be extended to a total of $812 million over 10 years.
It will develop essential drugs and not vaccines, officials explained.
"For far too long, we've relied on foreign manufacturing and supply chains for our most important medicines and active pharmaceutical ingredients while placing America's health, safety, and national security at grave risk," Peter Navarro, director of the White House Office of Trade and Manufacturing Policy, said in a statement.
Iran rejects Trump's talk of negotiation as Israel and Iran launch airstrikes
Cyprus has opened discussion with UK over its bases, president says
Netanyahu seeks to avoid snap vote as Iran war gives no boost in polls
Luxury Paris hotel near Elysee reopens after fire forces brief closure
Germany renews push for sugar tax and energy drinks ban for children
No injuries reported as drone attack hits fuel tank at Kuwait's airport
US expected to send thousands more soldiers to Middle East
Philippines works with Washington to obtain oil from US-sanctioned countries
